Resources

This study uses a high-throughput microfluidic platform to track thousands of CD33-redirected UniCAR-T cells at single-cell resolution. The analysis uncovers marked functional heterogeneity and identifies a potent subset of “serial killer” cells capable of eliminating multiple tumor targets. By integrating functional, kinetic and phenotypic readouts, the work provides new insights into UniCAR-T activity and supports the optimization of modular CAR-T therapies.

This study introduces an automated microfluidic assay for cytokine quantification in co-culture systems, reducing sample volume and improving reproducibility. The method shows strong correlation with standard flow cytometry and robust linearity in detecting IFN-γ across multiple E:T ratios. Automation minimizes user-dependent steps and significantly shortens hands-on time and data analysis, offering a faster and more reliable approach for immune activity assessment.

This study reports on using the Cellply CC-Array® microwell / fluorescence platform for high-throughput in vitro drug-response testing on primary multiple myeloma samples. The data demonstrate that the system can reliably detect drug sensitivity across different conditions, supporting functional precision medicine. This platform could accelerate screening and personalized therapy decisions by combining scalability, sensitivity, and ease of use.

Using VivaCyte and CC-Array microfluidics, this study miniaturized immune cell killing assays to generate 16 E:T ratios from very limited sample input. The platform delivered detailed, high-quality dose–response data while cutting manual steps and cell usage. Validation with NK cells confirmed accurate distributions, clear potency differences, and efficient kinetic analysis. This approach enables deeper characterization of cell therapies with minimal hands-on time.

Using a high-throughput microfluidic co-culture platform, this study profiles the single-cell killing dynamics of CD33-directed UniCAR-T cells. The analysis reveals distinct functional subpopulations and identifies a subset of potent serial killers capable of eliminating multiple tumor targets. These findings provide mechanistic insight into UniCAR-T functional heterogeneity and support the optimization of modular adapter-CAR systems.

A new AI tool called predicTCR can identify which T cells recognize cancer, using only single-cell sequencing data. This breakthrough speeds up the creation of personalized T-cell therapies and could broaden their use across cancer types.

This study introduces Inter-Cell Networking Profiling (ICNP), a micro-well–based approach that captures immune–tumor cell interactions with high sensitivity. By profiling effector–target clusters ex-vivo, ICNP reveals the immune-mediated activity of anti-CD38 therapy in multiple myeloma. The method offers a more comprehensive way to evaluate therapeutic responses and guide patient-specific treatment strategies.

This study investigates ex vivo drug response profiling in hematologic malignancies via the SMARTrial, showing that functional drug sensitivity testing can reliably report within a week for most patients. The authors demonstrate that resistance measured ex vivo predicts chemotherapy failure in vivo, and that this profiling enhances risk stratification beyond genetic markers.

This study introduces an inverted open microwell platform that efficiently traps, aggregates, and recovers live cells for downstream analysis. Using dielectrophoresis, the system enables gentle cluster manipulation while preserving viability. The approach supports high-throughput functional cell sorting and expands possibilities for studying cellular interactions in microfluidic environments.